BPC-157 vs Tadalafil
Extensively Studied vs FDA Approved
compatible No known pharmacological interaction. BPC-157's effects on angiogenesis and NO system may theoretically complement tadalafil, though clinical data on the combination is lacking.
Molecular Data
BPC-157 Tadalafil
Weight 1,419.53 Da 389.40 Da
Half-life <30 minutes ~17.5 hours
Chain 15 amino acids —
Type Pentadecapeptide Small molecule phosphodiesterase type 5 (PDE5) inhibitor
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Tadalafil
01 Long-acting duration with a 36-hour therapeutic window
02 Daily low-dose option (2.5-5mg) eliminates timing constraints
03 FDA-approved for both ED and BPH/LUTS
04 Minimal food interaction compared to other PDE5 inhibitors
05 Improved endothelial function and blood flow
06 Lower incidence of visual side effects vs. sildenafil
07 Potential benefits for exercise performance via enhanced blood flow
08 Well-established long-term safety profile
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Tadalafil
5mg daily or 10-20mg as-needed / Once daily or as-needed (max once per 24 hours)
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Tadalafil
Headache (11-15% incidence, most common side effect)
Dyspepsia / indigestion (4-13%)
Back pain (3-9%, relatively unique to tadalafil among PDE5 inhibitors)
Myalgia / muscle aches (1-7%, thought to be related to PDE11 inhibition)
Nasal congestion / rhinitis (3-5%)
Flushing (1-4%)
Limb pain (1-3%)
Dizziness (1-2%)
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Concurrent use of any organic nitrate medication (absolute contraindication)
Concurrent use of guanylate cyclase stimulators (e.g., riociguat)
Known hypersensitivity to tadalafil or any tablet excipient
Severe hepatic impairment (Child-Pugh Class C)
Recent stroke or myocardial infarction (within 90 days)
Unstable angina or angina during sexual intercourse
Uncontrolled hypertension (>170/100 mmHg) or hypotension (<90/50 mmHg)
NYHA Class IV heart failure
Hereditary degenerative retinal disorders (including retinitis pigmentosa)
History of NAION (relative contraindication -- increased recurrence risk)
Research Evidence
BPC-157 Tadalafil
Status Extensively Studied FDA Approved
References 8 studies 5 studies
Latest July 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.